Immix Biopharma clinical results show 89% CR rate as full cohort expands

Immix Biopharma is a clinical-stage biotech built around NXC-201, a CAR-T therapy being advanced through the fully enrolled, potentially registrational NEXICART-2 trial in relapsed/refractory AL amyloidosis. The company had already reported a 95% CR rate in the first 20 patients in May 2026, while topline data from the full 45-patient study had been expected in Q3 2026.

The full-cohort readout validates the response signal, but does not improve the headline rate. NXC-201 produced an 89% complete-response rate across all 45 patients, versus 95% in the earlier 20-patient subset. 〔0〕 The lower percentage is largely a denominator effect as the trial expanded, but it means the result is confirmation of an already strong signal rather than a clean upside surprise.

The newer patients still look encouraging beneath the headline number. All 25 newly added patients are either already in complete response or MRD-negative, with the company saying four pending MRD-negative patients could eventually lift the CR rate to 98%. 〔1〕 That supports the company’s argument that responses may deepen over time, but the 98% figure remains a projection based on conversion of pending patients, not an observed final result.

Durability and tolerability remain supportive, but are still immature. No relapses have been observed among patients who reached CR or MRD-negativity, and no neurotoxicity or enterocolitis has been observed to date. 〔2〕 〔3〕 These are meaningful positives for a CAR-T program, but follow-up remains ongoing and the filing does not provide mature duration-of-response data.

The program advances toward registration without removing the main development risk. NEXICART-2 is now fully enrolled, but the final readout and BLA submission are planned for 2027 rather than representing an approval or filing today. 〔4〕 The business remains dependent on converting this promising Phase 2 dataset into regulator-accepted evidence and funding the path to commercialization.

Bottom line: The update keeps NXC-201’s clinical story intact: exceptionally deep responses across a much larger cohort, but no headline improvement over the previously disclosed 95% rate. It is validation at the expected milestone, with the full readout and regulatory package still ahead.